More potent lipid-lowering effect by rosuvastatin compared with fluvastatin in everolimus-treated renal transplant recipients
| Autor: | Nils Tore Vethe, Anders Åsberg, Espen Molden, Ida Robertsen, Tone Granseth, Karsten Midtvedt, Morten Reier-Nilsen, Mwlod Ghareeb, Hallvard Holdaas, Fatemeh Akhlaghi |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Male
Indoles Genotype Atorvastatin Pharmacology Biology Article Fatty Acids Monounsaturated medicine Cytochrome P-450 CYP3A Humans Rosuvastatin Drug Interactions Everolimus Prospective Studies Rosuvastatin Calcium Fluvastatin Aged Dyslipidemias Sirolimus Transplantation Sulfonamides Drug Substitution Norway nutritional and metabolic diseases Middle Aged medicine.disease Kidney Transplantation Lipids Fluorobenzenes Phenotype Pyrimidines Treatment Outcome Female Hydroxymethylglutaryl-CoA Reductase Inhibitors Pravastatin Dyslipidemia Biomarkers Immunosuppressive Agents medicine.drug |
| Zdroj: | Transplantation. 97(12) |
| ISSN: | 1534-6080 |
| Popis: | BACKGROUND Dyslipidemia is a risk factor for premature cardiovascular morbidity and mortality in renal transplant recipients (RTRs). Pharmacotherapy with mTOR inhibitors aggravates dyslipidemia, thus necessitating lipid-lowering therapy with fluvastatin, pravastatin, or atorvastatin. These agents may not sufficiently lower lipid levels, and therefore, a more potent agent like rosuvastatin maybe needed. METHODS We have aimed to assess the lipid-lowering effect of rosuvastatin as compared with fluvastatin in RTR receiving everolimus. Safety was assessed as the pharmacokinetic (PK) interaction potential of a rosuvastatin/everolimus combination in RTR. A 12-hour everolimus PK investigation was performed in 12 stable RTR receiving everolimus and fluvastatin (80 mg/d). Patients were then switched to rosuvastatin (20 mg/d), and a follow-up 12/24-hour PK investigation of everolimus/rosuvastatin was performed after 1 month. All other drugs were kept unchanged. RESULTS In RTR already receiving fluvastatin, switching to rosuvastatin further decreased LDL cholesterol and total cholesterol by 30.2±12.2% (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|